Analyst ratings, especially downgrades, can significantly impact a stock's price in the short term. The downgrade from Buy to Hold by Stifel, a reputable financial services firm, along with the setting of a new price target at $65, suggests a bearish outlook on Bio-Techne's stock. This downgrade likely led to decreased investor confidence and a subsequent drop in the stock price. The high relevance score is due to the direct mention and focus on Bio-Techne, while the importance score reflects the significant impact analyst ratings can have on stock prices. The confidence level is high due to the clear cause-and-effect relationship between analyst downgrades and stock price movements.